Department of Pharmacology, Monash University, Parkville, Victoria, Australia.
Br J Pharmacol. 2012 May;166(1):98-109. doi: 10.1111/j.1476-5381.2011.01571.x.
The Secretin family of GPCRs are endocrine peptide hormone receptors that share a common genomic organization and are the subject of a wide variety of alternative splicing. All GPCRs contain a central seven transmembrane domain responsible for transducing signals from the outside of the cell as well as extracellular amino and intracellular carboxyl termini. Members of the Secretin receptor family have a relatively large N-terminus and a variety of lines of evidence support a common mode of ligand binding and a common ligand binding fold. These receptors are best characterized as coupling to intracellular signalling pathways via G(αs) and G(αq) but are also reported to couple to a multitude of other signalling pathways. The intracellular loops are implicated in regulating the interaction between the receptor and heterotrimeric G protein complexes. Alternative splicing of exons encoding both the extracellular N-terminal domain as well as the extracellular loops of some family members has been reported and as expected these splice variants display altered ligand affinity as well as differential activation by endogenous ligands. Various forms of alternative splicing have also been reported to alter intracellular loops 1 and 3 as well as the C-terminus and as one might expect these display differences in signalling bias towards downstream effectors. These diverse pharmacologies require that the physiological role of these splice variants be addressed but should provide unique opportunities for drug design and development.
分泌素家族 G 蛋白偶联受体是内分泌肽激素受体,它们具有共同的基因组组织,是多种选择性剪接的研究对象。所有 G 蛋白偶联受体都包含一个中央的七次跨膜结构域,负责将信号从细胞外部以及细胞外的氨基末端和细胞内的羧基末端传递。分泌素受体家族的成员具有相对较大的 N 末端,并且有多种证据支持共同的配体结合模式和共同的配体结合折叠。这些受体主要通过 G(αs)和 G(αq)与细胞内信号通路偶联,但也有报道称它们与多种其他信号通路偶联。细胞内环在调节受体与异三聚体 G 蛋白复合物之间的相互作用中起作用。已经报道了编码细胞外 N 末端结构域以及一些家族成员的细胞外环的外显子的选择性剪接,并且如预期的那样,这些剪接变体显示出改变的配体亲和力以及对内源性配体的不同激活。也已经报道了各种形式的选择性剪接会改变细胞内环 1 和 3 以及 C 末端,并且正如人们所预期的那样,这些会显示出对下游效应物的信号转导偏向的差异。这些不同的药理学要求解决这些剪接变体的生理作用,但应该为药物设计和开发提供独特的机会。